CY1116601T1 - Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της - Google Patents

Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της

Info

Publication number
CY1116601T1
CY1116601T1 CY20151100705T CY151100705T CY1116601T1 CY 1116601 T1 CY1116601 T1 CY 1116601T1 CY 20151100705 T CY20151100705 T CY 20151100705T CY 151100705 T CY151100705 T CY 151100705T CY 1116601 T1 CY1116601 T1 CY 1116601T1
Authority
CY
Cyprus
Prior art keywords
cholesterol
pharmaceutical composition
agent
prebiotic
production
Prior art date
Application number
CY20151100705T
Other languages
English (en)
Inventor
Boris Anatolievich Rudoy
Oleg Valentinovich Dorozhko
Original Assignee
Dikovskiy, Aleksander Vladimirovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dikovskiy, Aleksander Vladimirovich filed Critical Dikovskiy, Aleksander Vladimirovich
Publication of CY1116601T1 publication Critical patent/CY1116601T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση σχετίζεται με την ιατρική, ηπατολογία και φαρμακολογία και μπορεί να χρησιμοποιηθεί για την παραγωγή και χρήση φαρμακευτικής σύνθεσης βασιζόμενης σε ηπατοπροστατευτικό παράγοντα και πρεβιοτικό για τη θεραπευτική αγωγή και πρόληψη ηπατικών παθήσεων, οι οποίες προκαλούνται από ανταλλαγή λιπιδίων-χοληστερόλης και επιλέγονται από την ακόλουθη ομάδα: χολολιθίαση, κυρίως με λίθους χοληστερόλης, αλκοολική και μη-αλκοολική στεατοηπατίτιδα, χολική κίρρωση, βλάβη χοληδόχου κύστης αναστολής χοληστερόλης και επαγόμενη από φαρμακευτική ουσία και τοξική ηπατική βλάβη. Η φαρμακευτική σύνθεση χορηγείται από το στόμα και περιέχει ηπατοπροστατευτικό παράγοντα και πρεβιοτικό λαμβανόμενα, ως δραστικός παράγοντας, σε θεραπευτικώς αποτελεσματικές δόσεις. Η εφεύρεση συνεισφέρει στη λειτουργική αποκατάσταση του ήπατος σε βραχύ χρόνο και προλαμβάνει ενδεχόμενη υποτροπή πάθησης λόγω της αποκατάστασης της ανταλλαγής χοληστερόλης και της εντερικής βιοκοινότητας ως αποτέλεσμα της συνεργιστικής αλληλεπίδρασης του ηπατοπροστατευτικού παράγοντα και του πρεβιοτικού, προλαμβάνοντας έτσι παρενέργειες του ηπατοπροστατευτικού παράγοντα.
CY20151100705T 2008-03-04 2015-08-11 Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της CY1116601T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08873197.1A EP2266619B1 (de) 2008-03-04 2008-03-04 Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
PCT/RU2008/000122 WO2009110816A1 (ru) 2008-03-04 2008-03-04 Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение

Publications (1)

Publication Number Publication Date
CY1116601T1 true CY1116601T1 (el) 2017-03-15

Family

ID=41056233

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100705T CY1116601T1 (el) 2008-03-04 2015-08-11 Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της

Country Status (12)

Country Link
US (2) US9446058B2 (el)
EP (1) EP2266619B1 (el)
CN (1) CN102014960A (el)
BR (1) BRPI0822449A2 (el)
CY (1) CY1116601T1 (el)
DK (1) DK2266619T3 (el)
EA (1) EA019985B1 (el)
ES (1) ES2545105T3 (el)
HR (1) HRP20150849T1 (el)
PL (1) PL2266619T3 (el)
SI (1) SI2266619T1 (el)
WO (1) WO2009110816A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013103250A1 (ko) * 2012-01-06 2013-07-11 주식회사 대웅제약 타우로우루소데옥시콜릭산을 포함하는 조성물
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
CN106509889A (zh) * 2016-11-04 2017-03-22 山东维尼莱生物科技股份有限公司 一种对酒精性肝损伤有辅助保护作用的保健品
JP6772773B2 (ja) * 2016-11-14 2020-10-21 ブラザー工業株式会社 通信装置
CN111494333B (zh) * 2020-04-14 2022-06-14 安士制药（中山）有限公司 一种熊去氧胆酸胶囊及其制备方法
JP2023524579A (ja) * 2020-05-05 2023-06-12 ネフミ フィルホ ヴィクトル アボウ ヒトの神経・免疫・内分泌及びコルチゾール減少系の調節組成物
CN115040545A (zh) * 2022-06-13 2022-09-13 江南大学 鸡胆粉在制备解酒护肝药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
BR0108080A (pt) 2000-02-04 2006-02-07 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
JP3908513B2 (ja) 2001-11-19 2007-04-25 日本甜菜製糖株式会社 肝機能改善剤
RU2205637C1 (ru) * 2002-04-24 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Гепатопротекторное средство "карсилин"
BG108250U (en) 2003-10-10 2005-04-30 "Софарма" Ад Probiotic food additive
CZ20033042A3 (cs) * 2003-11-10 2005-06-15 Naturprodukt Cz Spol. S R. O. Potravinový doplněk na bázi silymarinu
HUP0500582A1 (hu) * 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok
RU2310463C1 (ru) * 2006-05-19 2007-11-20 Закрытое акционерное общество "Партнер" Гепатопротекторный пробиотик

Also Published As

Publication number Publication date
EP2266619A4 (de) 2011-07-20
DK2266619T3 (en) 2015-08-24
EA201001100A1 (ru) 2011-02-28
US20160354387A1 (en) 2016-12-08
SI2266619T1 (sl) 2015-11-30
EA019985B1 (ru) 2014-07-30
CN102014960A (zh) 2011-04-13
WO2009110816A1 (ru) 2009-09-11
EP2266619A1 (de) 2010-12-29
HRP20150849T1 (hr) 2015-09-25
ES2545105T3 (es) 2015-09-08
EP2266619B1 (de) 2015-05-13
US20110312910A1 (en) 2011-12-22
BRPI0822449A2 (pt) 2015-06-16
PL2266619T3 (pl) 2015-10-30
US9446058B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
CY1116601T1 (el) Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
De Paz-Campos et al. Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats
NO20075344L (no) Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
NO20084256L (no) DPP IV inhibitorformuleringer
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
JP2010518122A5 (el)
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA200701746A1 (ru) Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
AR061289A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
UY27462A1 (es) Derivados de quinolina
EP1993519A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING THE ABUSE OF ORGANIC PRODUCTS MANIPULATED ORAL
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
BRPI0514254A (pt) uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal